NCT05872139

Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging

Completed NA Last updated 24 May 2023

What this trial tests

NA trial testing Placebo in Aging in 23 participants. Completed in 1 May 2023.

Timeline

23 September 2022

Primary endpoint
17 April 2023

1 May 2023

Quick facts

Lead sponsor	Ball State University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	other
Enrollment	23
Start date	23 September 2022
Primary completion	17 April 2023
Estimated completion	1 May 2023
Sites	1 location across United States

Drugs / interventions tested

• Placebo
• Mitoquinone Mesylate — full drug profile →

Conditions studied

• Aging — all drugs for Aging →
• Endothelial Dysfunction — all drugs for Endothelial Dysfunction →
• Cardiovascular Function — all drugs for Cardiovascular Function →
• Arterial Stiffness — all drugs for Arterial Stiffness →

Sponsor

Ball State University

Who can join

18 and older, any sex, with Aging or Endothelial Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary goal of this intervention is to determine the efficacy of acute mitochondrial-specific antioxidants to improve vascular endothelial function in middle-aged and older (≥45 y) adults who do no perform regular aerobic exercise. In a double-blind, randomized, placebo-controlled crossover design participants with receive both MitoQ and placebo arm of the study. Primary endpoints will include vascular endothelial function assessed by brachial artery flow-mediated dilation and cardiac function assessed via pulse wave analysis. Secondary endpoints will include measures of aortic stiffness assessed by carotid-femoral pulse wave velocity and carotid artery stiffness (e.g. β-stiffness) and elasticity (carotid compliance, distensibility, and Youngs elastic modulus) from ultrasonography.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Multifaceted functions of Drp1 in hypoxia/ischemia-induced mitochondrial quality imbalance: from regulatory mechanism to targeted therapeutic strategy.
   Hao S, Huang H, Ma RY, Zeng X, et al · · 2023 · cited 28× · PMID 37833768 · DOI 10.1186/s40779-023-00482-8
2. Mitochondria-targeted nanotechnology in cardiovascular diseases: a review of recent advances.
   Sun S, Wu M, Zhang P, Sun L, et al · · 2026 · PMID 42022751 · DOI 10.1093/rb/rbag040
3. Cardiovascular ageing: hallmarks, signaling pathways, diseases and therapeutic targets.
   Zheng P, Yan W, Ding Y, Zhang Y, et al · · 2026 · PMID 42010239 · DOI 10.1038/s41392-026-02630-7